Loading
PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
An immunoglobulin-domain receptor with an ITIM-like tail; part of the CD226/TIGIT/CD96/PVRIG axis over CD155 and CD112.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"PVRIG" OR ABSTRACT:"PVRIG" OR TITLE:"CD112R" OR ABSTRACT:"CD112R" OR TITLE:"PVR related immunoglobulin domain containing" OR ABSTRACT:"PVR related immunoglobulin domain containing" OR TITLE:"C7orf15" OR ABSTRACT:"C7orf15") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PVRIG (CD112R), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/pvrig.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/pvrig.json. Licence CC BY-NC 4.0.